Continuing the acquisition spree after absorbing Arena Pharmaceuticals and Reviral Ltd. to meet unmet patients’ needs, Pfizer Inc. (NYSE: PFE), the global pharmaceutical and biotechnology company, has agreed to snap up migraine drugmaker Biohaven Pharmaceutical Holding Company Ltd. (BHVN).  The cash deal is valued at $11.6 billion, to be funded by Pfizer with current cash in hand.   Following the news, shares of Pfizer rose 1.66% on Tuesday at the close, while shares of Biohaven skyrocketed 68.4%.  The deal followed the strategic partnership deal between the two, entered in November 2021, for the commercialization of rimegepant and zavegepant outside the U.S.
https://www.tipranks.com/news/pfizer-vying-for-valuable-upside?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Jun 2022 até Jul 2022 Click aqui para mais gráficos Pfizer.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Jul 2021 até Jul 2022 Click aqui para mais gráficos Pfizer.